# Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)

> **NCT00431145** · PHASE2 · UNKNOWN · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 80 (—)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Niacin
- **DRUG:** Niacin+Statin

## Key facts

- **NCT ID:** NCT00431145
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 80 (—)
- **Last updated:** 2007-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00431145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00431145, "Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT00431145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*